Guess how much $5,000 invested in Sigma shares in December 2023 is worth now!

Sigma shares have soared over the past year alongside the merger with Chemist Warehouse.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sigma Healthcare Ltd (ASX: SIG) shares have been on a tear this past year.

Shares in the S&P/ASX 200 Index (ASX: XJO) healthcare stock – which owns chemists including Amcal, Discount Drug Stores, and Guardian Pharmacy – really took off a bit over a year ago, in December 2023.

That's when Sigma first announced its $30 billion merger intentions with privately owned Chemist Warehouse.

As those merger plans progressed throughout 2024 and into 2025, Sigma shares made some ASX investors very happy.

How happy?

Let's have a look.

Six smiling health workers pose for a selfie.

Image source: Getty Images

What $5,000 invested in Sigma shares last December is worth today

If you had a working time machine, you could pop back to 1 December 2023 and snap up Sigma shares for 69 cents apiece.

This means your $5,000 investment would have netted you 7,246 shares (ignoring brokerage fees).

In late afternoon trade today, those same shares are changing hands for $2.75 apiece.

That means the Sigma shares you bought on 1 December 2023 for $5,000, less than 15 months ago mind you, is now worth a whopping $19,926.50. Or a gain of 298.6%.

But we're not quite done with the maths yet.

Adding a little icing to this highly profitable cake, you'd also have received a total of 1 cent per share in partly franked dividends over this period.

Which would bring your total returns on the initial $5,000 investment to $19,998.96.

Now, when you're done with the time machine, can you please drop it by my office!

What's the latest on the pending merger with Chemist Warehouse?

On 30 January, ASX 200 investors learned that, as expected, Sigma shareholders had voted to approve the merger with Chemist Warehouse, with 99.86% voting 'yes'.

Sigma shareholders also agreed to elect four Chemist Warehouse executives to the Sigma board.

The Chemist Warehouse board's vote to approve the merger received 99.23% support.

Commenting on the merger on the day, Sigma chair Michael Sammells said:

Sigma has world-class distribution infrastructure and capability that is delivering best in class service to pharmacies across Australia every day.

Chemist Warehouse has unparalleled pharmacy franchise and marketing know-how and expertise which will also help elevate our support for our Amcal and Discount Drug Store franchisees.

Given the nature and value accretion of the proposed transaction, Sigma Directors unanimously recommend that shareholders vote in favour of the resolutions.

Sigma shares had been in a trading halt the day before and closed down 3.6% following the news.

Though, as we saw above, that hardly crimped the returns investors have reaped since the merger news first broke in December 2023.

The merger process was finalised this afternoon when Sigma announced that its 100% acquisition of issued shares in Chemist Warehouse via a scheme of arrangement was implemented today.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Silver dice with buy and sell written on them on top of stock market charts.
Healthcare Shares

CSL shares have surged 49%: Are brokers finally turning bullish?

CSL’s recovery is gathering pace, but has the share price already priced in the turnaround?

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals FY26 earnings: Revenue jumps, losses widen as clinical pipeline progresses

Clarity Pharmaceuticals reported strong FY26 revenue growth, a wider loss, and progress towards commercialisation of its radiopharmaceutical pipeline.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Clinuvel Pharmaceuticals posts 10th consecutive profit and maintains dividend

Clinuvel Pharmaceuticals reported its tenth straight profit, rising cash reserves, and steady dividend for FY2026.

Read more »

Man and woman sitting at table with the man looking a bit puzzled at his laptop.
Healthcare Shares

Should I buy CSL shares before the end of August?

I think the company's earnings outlook is starting to look more encouraging.

Read more »

Female pharmacist smiles with a digital tablet.
Earnings Results

Sigma Healthcare FY26 earnings: Record profit as Chemist Warehouse merger delivers growth

The company reported double-digit revenue growth.

Read more »

Health professional working on his laptop.
Earnings Results

Mesoblast earnings: Strong revenue growth and operational milestones in FY26

The biotech has reported a significant jump in revenue.

Read more »

Two lab workers fist pump each other.
Earnings Results

Ramsay Health Care FY26: Profit surges on transformation momentum

The results show stronger profit growth, a higher dividend, and continued momentum in its transformation plans.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Starpharma: FY26 earnings reveal strong revenue growth and improved loss

Starpharma posted a sharp rise in FY26 revenue and narrowed its loss, with new funds extending its cash runway into…

Read more »